Horizon 2020: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence

Demands of cancer care in Europe is significantly increasing as the number of cases is growing as well. Furthermore, it is expected to increase by 14.1% by 2030.

Patients, experts and citizens are demanding new treatments to fight cancer as the knowledge of the biological complexity of cancer is wider due to new studies and the application of new technologies and tools such as Artifitial Intelligence.

Thus, the scope of this call is to establish guideline-based decision support and platform solution to generate knoewledge discovery for breast, lung and prostate cancer with applicablility to other indications. The funded action will only focus in breast, lung and prostate cancer.

The proposals submitted should describe how the results of the project will contribute in the effects described in the call wherever possible baseline, targets and metrics to measure impact.

Requirements

The proposals shall comply the conditions described in the Rules for paticipation in Horizon 2020 regarding IMI2 JU.

Submission and evalution, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submisison, evaluation and grant award.

Opening date

23 de junio de 2020

1st stage Deadline

29 de septiembre de 2020 a las 17:00 (Horario de Bruselas)

2nd stage Deadline

17 de marzo de 2021 a las 17:00 (Horario de Bruselas)

Further information

SEDIA

Related Documents

Rules for participation in Horizon 2020

IMI2 Manual for submisison, evaluation and grant award